title: Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression.
abstract: BACKGROUND
  The aim of this prospective study was to verify whether magnetostimulation with weak variable magnetic fields with low value of induction could enhance the effects of pharmacological therapy in drug-resistant depression.
  
  
  METHODS
  Thirty patients, 26 women and 4 men, with drug-resistant depression were enrolled in the study. The subjects from Group No. I (14 patients) were given fluvoxamine and treated with weak variable magnetic field using the VIOFOR JPS device; the subjects from Group No. II (16 patients) were also given fluvoxamine but they were treated with the VIOFOR JPS device in placebo mode. Changes in depressive symptoms were estimated with the 21-point Hamilton Depression Scale (HDRS), Montgomery-Asberg Depression Scale (MADRS) and Beck Depression Inventory (BDI) questionnaire.
  
  
  RESULTS
  After 15 days of treatment highly significant differences were revealed between the patients treated with magnetic field and the patients treated with placebo: the final HDRS score was 53% of the initial value for the group receiving combined treatment, and 86% in the placebo group (p<0.001); for MADRS score the values were 51% and 88% (p<0.001), respectively, and for BDI 60% and 87% (p<0.001). Thus, the average effect of placebo applied with fluvoxamine was a ca. 15% reduction of symptoms, while the concurrent application of magnetic field and SSRI treatment resulted in a 40-50% improvement.
  
  
  CONCLUSIONS
  Our study indicates that adding a two-week low-induction variable magnetic field stimulation to a classical pharmacologic therapy reduces the intensity of symptoms in patients with drug-resistant depressive disorders.
authors.affiliation: Department of Psychiatry, Medical University of Silesia, Zabrze, Poland. jaroslaw.sobis@poczta.onet.pl
authors.forename: Jarosław
authors.initials: J
authors.lastname: Sobiś
authors.forename: Magdalena
authors.initials: M
authors.lastname: Jarzab
authors.forename: Robert Teodor
authors.initials: RT
authors.lastname: Hese
authors.forename: Aleksander
authors.initials: A
authors.lastname: Sieroń
authors.forename: Tomasz
authors.initials: T
authors.lastname: Zyss
authors.forename: Piotr
authors.initials: P
authors.lastname: Gorczyca
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Gierlotka
authors.forename: Robert
authors.initials: R
authors.lastname: Pudlo
authors.forename: Jerzy
authors.initials: J
authors.lastname: Matysiakiewicz
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D011446:Prospective Studies; D050781:Transcranial Magnetic Stimulation / Q000379:methods*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016666:Fluvoxamine